Metagenomi Inc. Common St... (MGX)
2.77
-0.14 (-4.81%)
At close: Jan 14, 2025, 3:59 PM
2.75
-0.53%
After-hours Jan 14, 2025, 06:05 PM EST
undefined% (undefined)
| Bid | 2.75 |
| Market Cap | 103.48M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.24 |
| PE Ratio (ttm) | -1.23 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 2.81 |
| Volume | 479,835 |
| Avg. Volume (20D) | 1,935,972 |
| Open | 2.97 |
| Previous Close | 2.91 |
| Day's Range | 2.67 - 2.97 |
| 52-Week Range | 1.61 - 12.74 |
| Beta | undefined |
About MGX
Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and lice...
Industry Biotechnology
Sector Healthcare
IPO Date Apr 6, 2006
Employees 236
Stock Exchange NASDAQ
Ticker Symbol MGX
Website https://www.metagenomi.co
Analyst Forecast
According to 7 analyst ratings, the average rating for MGX stock is "Buy." The 12-month stock price forecast is $16, which is an increase of 478.66% from the latest price.
Buy 85.71%
Hold 14.29%
Sell 0.00%
8 months ago ·
Source
-12.36%
Metagenomi shares are trading lower after Moderna ...
Unlock content with
Pro Subscription
